Ironwood Pharmaceuticals, Inc.
A Boston-based biotechnology company that develops and sells medicines for digestive and rare diseases, best known for Linzess, a prescription treatment for chronic constipation and irritable bowel syndrome. It began in 1998 as Microbia, founded by postdocs from a Whitehead Institute lab, and renamed itself Ironwood in 2008 after the long-lived desert tree that shelters other plants — a nod to endurance. Its flagship drug linaclotide was discovered by those same early researchers.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Armistice Capital, LLC | 13G/APassive | 8.43% | 13.93M | Aug 14, 2026 |
| Steven Boyd | 13G/APassive | 8.43% | 13.93M | Aug 14, 2026 |
| STATE STREET CORPORATION | 13GPassive | 5.4% | 8.81M | Aug 7, 2026 |
| BlackRock, Inc. | 13G/APassive | 8.1% | 13.37M | Jul 28, 2026 |
| Renaissance Technologies LLC | 13G/APassive | 4.9% | 8.06M | May 14, 2026 |
| Renaissance Technologies Holdings Corporation | 13G/APassive | 4.9% | 8.06M | May 14, 2026 |
| BANK OF AMERICA CORP /DE/ | 13G/APassive | 6.1% | 9.96M | Apr 27, 2026 |
| The Vanguard Group | 13G/APassive | 0% | 0 | Mar 27, 2026 |
| Alexander J. Denner | 13D/AActivist | 5.8% | 9.44M | Mar 19, 2026 |
| Sarissa Capital Management LP | 13D/AActivist | 5.6% | 9.19M | Mar 19, 2026 |